Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Cp (NQ: ABUS )

1.900 +0.050 (+2.70%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arbutus Biopharma Cp

< Previous 1 2 Next >
Arbutus to Participate in Three Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces Resignation of Board Member
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
From Arbutus Biopharma Corporation
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.